Patents by Inventor Ann Chen

Ann Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human IgG autoantibodies against galactose-deficient IgA1, preparation method thereof, and use thereof
    Patent number: 12650431
    Abstract: The current invention provides high specificity monoclonal antibodies, which can specifically bind to Gd-IgA as a novel non-invasive method for rapid diagnosing of IgAN subjects, which can be applied to unravel the mechanisms of IgA nephropathy and establish therapeutical strategies.
    Type: Grant
    Filed: March 8, 2023
    Date of Patent: June 9, 2026
    Assignee: National Defense Medical University
    Inventors: Shuk-Man Ka, Chia-Chao Wu, Ann Chen
  • Method for ameliorating progression of renal fibrosis and treating renal fibrosis by 5-(2?,4?-difluorophenyl)-salicylanilide derivatives
    Patent number: 12478632
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using a pharmaceutical composition of 5-(2?,4?-difluorophenyl)-salicylanilide derivatives and their ring-fused analogs for inhibiting, reducing, or treating chronic kidney disease or/and renal fibrosis, conditions leading to or arising from it, and/or negative effects of each thereof.
    Type: Grant
    Filed: October 10, 2023
    Date of Patent: November 25, 2025
    Assignee: NATIONAL DEFENSE MEDICAL UNIVERSITY
    Inventors: Shuk-Man Ka, Hsu-shan Huang, Ann Chen
  • Tris DBA pharmaceutical composition and its use for treating autoimmune diseases
    Patent number: 12090132
    Abstract: The invention relates to a new use of Tris (dibenzylideneacetone) dipalladium (Tris DBA). The invention provides a pharmaceutical composition comprising Tris DBA, and a use of the pharmaceutical composition for treating autoimmune diseases, such as, Multiple sclerosis, psoriasis, asthma, systemic lupus erythematosus and lupus nephritis.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: September 17, 2024
    Assignee: NATIONAL DEFENSE MEDICAL CENTER
    Inventors: Ann Chen, Shuk-Man Ka
  • Diagnostic kits and methods configured to rapidly and non-invasively determine physiologic levels of galactose-deficient IgA1 (Gd-IgA1) in the subject of IgA nephropathy
    Patent number: 12000841
    Abstract: The present invention provides a lectin from Crenomytilus grayanus or Mytilus trossulus as diagnostic reagents for IgA nephropathy. The present invention also provides a diagnostic kit for detecting Galactose-deficient IgA1 (Gd-IgA1), comprising RussiaSea-001 (also called as CGL) isolated from Crenomytilus grayanus or RussiaSea-002 (also called as MTL) isolated from Mytilus trossulus. The present invention further provides a method for detecting Gd-IgA1 using RussiaSea-001 or RussiaSea-002.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: June 4, 2024
    Assignee: NATIONAL DEFENSE MEDICAL CENTER & ACADEMIA SINICA
    Inventors: Ann Chen, Shuk-Man Ka, Shih-Hsiung Wu
  • METHOD FOR AMELIORATING PROGRESSION OF RENAL FIBROSIS AND TREATING RENAL FIBROSIS BY 5-(2',4'-DIFLUOROPHENYL)-SALICYLANILIDE DERIVATIVES
    Publication number: 20240033271
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using a pharmaceutical composition of 5-(2?,4?-difluorophenyl)-salicylanilide derivatives and their ring-fused analogs for inhibiting, reducing, or treating chronic kidney disease or/and renal fibrosis, conditions leading to or arising from it, and/or negative effects of each thereof.
    Type: Application
    Filed: October 10, 2023
    Publication date: February 1, 2024
    Inventors: Shuk-Man KA, Hsu-shan HUANG, Ann CHEN
  • Human IgG autoantibodies against galactose-deficient IgA1, preparation method thereof, and use thereof
    Publication number: 20230400468
    Abstract: The current invention provides high specificity monoclonal antibodies, which can specifically bind to Gd-IgA as a novel non-invasive method for rapid diagnosing of IgAN subjects, which can be applied to unravel the mechanisms of IgA nephropathy and establish therapeutical strategies.
    Type: Application
    Filed: March 8, 2023
    Publication date: December 14, 2023
    Inventors: Shuk-Man KA, Chia-Chao Wu, Ann CHEN
  • PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR RELIEVING PROGRESSION OF CHRONIC KIDNEY DISEASE OR PREVENTING THEREOF
    Publication number: 20220354872
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using a pharmaceutical composition of 5-(2?,4?-difluorophenyl)-salicylanilide derivatives and their ring-fused analogs for preventing, inhibiting, reducing, or treating chronic kidney disease, conditions leading to or arising from it, and/or negative effects of each thereof.
    Type: Application
    Filed: May 5, 2021
    Publication date: November 10, 2022
    Inventors: Shuk-Man KA, Hsu-shan HUANG, Ann CHEN
  • MOUSE MONOCLONAL ANTIBODIES AGAINST GALACTOSE-DEFICIENT IGA1,PREPARATION METHOD THEREOF, AND USE THEREOF
    Publication number: 20220275106
    Abstract: The current invention provides high specificity mouse monoclonal antibodies, which can specifically bind to Gd-IgA as a novel non-invasive method for rapid diagnosing of IgAN subjects, can be applied to unravel the mechanisms of IgA nephropathy and establish therapeutical strategies.
    Type: Application
    Filed: March 1, 2022
    Publication date: September 1, 2022
    Inventors: Ann CHEN, Shuk-Man KA
  • TRIS DBA PHARMACEUTICAL COMPOSITION AND ITS USE FOR TREATING AUTOIMMUNE DISEASES
    Publication number: 20210186919
    Abstract: The invention relates to a new use of Tris (dibenzylideneacetone) dipalladium (Tris DBA). The invention provides a pharmaceutical composition comprising Tris DBA, and a use of the pharmaceutical composition for treating autoimmune diseases, such as, Multiple sclerosis, psoriasis, asthma, systemic lupus erythematosus and lupus nephritis.
    Type: Application
    Filed: July 14, 2020
    Publication date: June 24, 2021
    Inventors: Ann CHEN, Shuk-Man KA
  • DIAGNOSTIC KITS AND METHODS CONFIGURED TO RAPIDLY AND NON-INVASIVELY DETERMINE PHYSIOLOGIC LEVELS OF GALACTOSE-DEFICIENT IGA1 (GD-IGA1) IN THE SUBJECT OF IGA NEPHROPATHY
    Publication number: 20210123927
    Abstract: The present invention provides a lectin from Crenomytilus grayanus or Mytilus trossulus as diagnostic reagents for IgA nephropathy. The present invention also provides a diagnostic kit for detecting Galactose-deficient IgA1 (Gd-IgA1), comprising RussiaSea-001 (also called as CGL) isolated from Crenomytilus grayanus or RussiaSea-002 (also called as MTL) isolated from Mytilus trossulus.
    Type: Application
    Filed: October 29, 2020
    Publication date: April 29, 2021
    Inventors: Ann CHEN, Shuk-Man KA, Shih-Hsiung WU
  • USE OF GINSENOSIDE M1 FOR INHIBITING RENAL FIBROSIS
    Publication number: 20170087170
    Abstract: The present invention provides a method of inhibiting renal fibrosis in a subject in need thereof.
    Type: Application
    Filed: May 18, 2015
    Publication date: March 30, 2017
    Inventors: SHEAU-LONG LEE, YU-CHIEH LEE, ANN CHEN, KUO-FENG HUA, SHUK-MAN KA
  • Use of osthole for treating focal segmental glomerulosclerosis
    Patent number: 9393226
    Abstract: The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage/lymphocyte infiltration in the kidney, etc.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: July 19, 2016
    Assignee: National Defense Medical Center
    Inventors: Shuk-Man Ka, Ann Chen, Kuo-Feng Hua, Kuo-Ping Chao, Shun-Min Yang
  • Use of hydroxycinnamaldehyde glycoside derivatives for treating glomerulonephritis
    Patent number: 9321795
    Abstract: The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 26, 2016
    Assignee: National Defense Medical Center
    Inventors: Ann Chen, Shuk-Man Ka, Kuo-Feng Hua, Shui-Tein Chen, Kuo-Ping Chao
  • Treatment for nephritis
    Patent number: 9295705
    Abstract: This invention relates to methods for treatment of nephritis. This invention further provides a method of treating with nephritis comprising administering to the subject an amount of herbal pharmaceutical composition thereof effective to treat the subject. Move particularly, this invention provides an herbal pharmaceutical composition comprising Rhizoma Atractylodis macrocephalae, Eucommiae cortex, Lonicerae caulis, and Hedyotidis diffusae Herba thereof for use in treating a subject afflicted with active nephritis.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: March 29, 2016
    Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: Ann Chen, Shuk-Man Ka, Rey-Yuh Wu, Jia-Ming Chang
  • USE OF OSTHOLE FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS
    Publication number: 20150297560
    Abstract: The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage/lymphocyte infiltration in the kidney, etc.
    Type: Application
    Filed: April 22, 2015
    Publication date: October 22, 2015
    Inventors: Shuk-Man KA, Ann CHEN, Kuo-Feng HUA, Kuo-Ping CHAO, Shun-Min YANG
  • USE OF HYDROXYCINNAMALDEHYDE GLYCOSIDE DERIVATIVES FOR TREATING GLOMERULONEPHRITIS
    Publication number: 20150299242
    Abstract: The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc.
    Type: Application
    Filed: April 22, 2015
    Publication date: October 22, 2015
    Inventors: Ann CHEN, Shuk-Man KA, Kuo-Feng HUA, Shui-Tein Chen, Kuo-Ping CHAO
  • SGLT2 AS BIOMARKER FOR DIAGNOSING CHRONIC KIDNEY DISEASE AND MONITORING THE DISEASE STATUS AFTER TREATMENT
    Publication number: 20150104881
    Abstract: The present invention relates to a method for diagnosis of a chronic kidney disease in a subject by detecting the expression level of a sodium-glucose linked transporter 2 (SGLT2) protein in urine samples. A method for monitoring progression of a chronic kidney disease in a patient is also provided.
    Type: Application
    Filed: October 13, 2014
    Publication date: April 16, 2015
    Inventors: Ann CHEN, Shuk-Man KA
  • Use of citral for treating focal segmental glomerulosclerosis
    Patent number: 8993637
    Abstract: The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: March 31, 2015
    Assignee: National Defense Medical Center
    Inventors: Ann Chen, Kuo-Feng Hua, Shuk-Man Ka, Kuo-Ping Chao, Wen-Liang Chang, Kuo-Yuan Hwa
  • Bottle
    Patent number: D886626
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: June 9, 2020
    Assignee: Diageo Brands B.V.
    Inventors: Andrew Fell, Ann Chen, Nicolas Johnson
  • Bottle
    Patent number: D987439
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: May 30, 2023
    Assignee: Diageo Brands B.V.
    Inventors: Andrew Fell, Ann Chen, Nicolas Johnson